68,292 Shares in Bruker Corporation $BRKR Acquired by PDT Partners LLC

PDT Partners LLC acquired a new stake in Bruker Corporation (NASDAQ:BRKR) in the 2nd quarter, HoldingsChannel reports. The institutional investor acquired 68,292 shares of the medical research company’s stock, valued at approximately $4,110,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Los Angeles Capital Management LLC acquired a new stake in Bruker during the 4th quarter worth $26,000. Allworth Financial LP raised its position in shares of Bruker by 40.6% in the third quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock valued at $29,000 after buying an additional 257 shares during the last quarter. Essential Partners LLC purchased a new position in shares of Bruker in the first quarter worth about $36,000. Global Retirement Partners LLC purchased a new position in shares of Bruker in the second quarter worth about $38,000. Finally, Parallel Advisors LLC boosted its position in Bruker by 121.0% during the fourth quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock worth $41,000 after acquiring an additional 479 shares during the last quarter. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Leerink Partners increased their price objective on shares of Bruker from $60.00 to $70.00 and gave the company an “outperform” rating in a report on Tuesday, July 7th. Wall Street Zen upgraded Bruker from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Guggenheim increased their price target on Bruker from $50.00 to $70.00 and gave the company a “buy” rating in a report on Monday, June 29th. TD Cowen reiterated a “hold” rating on shares of Bruker in a research report on Wednesday, July 15th. Finally, Weiss Ratings raised Bruker from a “sell (d)” rating to a “sell (d+)” rating in a research note on Wednesday, June 3rd. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $56.64.

Bruker Stock Down 0.2%

BRKR stock opened at $56.85 on Wednesday. Bruker Corporation has a one year low of $28.53 and a one year high of $65.30. The firm has a market cap of $8.66 billion, a PE ratio of -81.21, a PEG ratio of 1.74 and a beta of 1.28. The firm’s 50 day moving average price is $58.69 and its 200-day moving average price is $47.71. The company has a debt-to-equity ratio of 0.76, a quick ratio of 0.92 and a current ratio of 1.85.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings data on Tuesday, August 4th. The medical research company reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.11. The company had revenue of $838.50 million during the quarter, compared to analyst estimates of $853.57 million. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%.The firm’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period in the prior year, the business posted $0.32 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, equities research analysts anticipate that Bruker Corporation will post 2.12 EPS for the current year.

Bruker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Monday, September 21st will be issued a dividend of $0.05 per share. The ex-dividend date is Monday, September 21st. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.4%. Bruker’s dividend payout ratio is currently -28.57%.

Bruker Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.